Nasopharynx Cancer
Conditions
Brief summary
This research aims to assess both effectiveness and safety of combining R-GEP regimen comprising gemcitabine, recombinant human endostatin, and cerexinib with low- and high-dose radiotherapy in managing unresectable recurrent nasopharyngeal carcinoma.
Detailed description
Eligible patients will undergo screening before enrolling in this trial 。 The participants will receive R-GEP therapy according to specified dosing schedules over six cycles. Additionally administered low-dose radiotherapy during specific cycles serves to modulate immune microenvironment while high-dose fractionated radiotherapy follows completion of GEP therapy courses. Maintenance immunotherapy continues up until one year post-treatment conclusion or disease progression.Finally, the participants were evaluated accordingly。
Interventions
DRUGGEP (Gemcitabine, Recombinant Human Endostatin, and Carrellizumab) Combined With High-low-dose Radiotherapy
The R-GEP regimen is as follows: Gemcitabine (G; 1.0 g/m2, d1, d8) in combination with recombinant human vascular endothelial growth factor (E; 150 mg, continuous intravenous infusion for 72 hours) and Carelizumab (P; 200 mg), administered every three weeks for a total of six cycles. During the 2nd-4th cycles, low-dose radiotherapy is administered to modulate the immune microenvironment (R: one course of radiotherapy per cycle: including booster fractions of 1 Gy\*3 times for the recurrent lesions, once a day, for three cycles). Approximately three weeks after the completion of the sixth cycle of GEP regimen (or the last cycle), high-dose fractionated radiotherapy (5-8 Gy\*5 times, once a day) is given to the recurrent lesions. Immune maintenance therapy continues until one year after treatment completion or disease progression.
Sponsors
Zhejiang Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients aged ≥18 years; 2. ECOG performance status 0-2; 3. Pathological or clinical imaging diagnosis of recurrent nasopharyngeal carcinoma; 4. With imaging assessable lesions (assessed by RECIST 1.1 criteria); 5. Recurrent lesions are not eligible for curative local treatment (including but not limited to extensive invasion of recurrent lesions; recurrent lesions with obvious necrosis or ulceration, with bleeding risk; recurrent lesions extensively invading surrounding nerves/vessels or skin/muscle; obvious late radiation therapy complications after previous treatment: radiation-induced brain injury, posterior cranial nerve injury, dysphagia, severe myofibrosis; second or multiple courses of radiation therapy after recurrence or multiple recurrences); 6. The following requirements must be met for the function of major organs: Hematological parameters tolerable to treatment: white blood cells ≥3.0×10\^9/L, neutrophils ≥1.5×10\^9/L, hemoglobin ≥9 g/dL, platelets ≥90×10\^9/L. Liver and kidney function: ALT, AST \<1.5 times the upper limit of normal (ULN), total bilirubin \<1.5×ULN, serum creatinine (Cr) ≤1.5×ULN; Echocardiographic assessment, left ventricular EF ≥50%; 7. The patient has signed an informed consent form and is willing and able to comply with the visit schedule, treatment plan, laboratory tests, and other research procedures. 8. Voluntarily enroll in this study, sign an informed consent form, have good compliance and willingness to cooperate with follow-up.
Exclusion criteria
1. Subjects who cannot accept or tolerate chemotherapy or radiotherapy for various reasons; 2. Subjects who can be cured by definitive radiotherapy or surgery; 3. Subjects who have undergone major surgical procedures within the past 4 weeks or have not fully recovered from such procedures; 4. Subjects who are currently participating in other drug clinical trials; 5. Serious cardiac disease or discomfort, including but not limited to the following conditions: * History of congestive heart failure or impaired systolic function (LVEF \<50%); * Uncontrolled high-risk arrhythmias, such as atrial tachycardia, resting heart rate \>100bpm, significant ventricular arrhythmias (such as ventricular tachycardia) or higher-level atrioventricular conduction block (i.e., Mobitz Ⅱ second-degree atrioventricular conduction block or third-degree atrioventricular conduction block); * Angina requiring anti-angina drug therapy; * Clinically significant valvular heart disease; * ECG showing a penetrating myocardial infarction; * Uncontrolled hypertension (systolic blood pressure \>180mmHg and/or diastolic blood pressure \>100mmHg); 6. Subjects who have a history of hypersensitivity to any component of the study drug; 7. Any other situation in which the investigator deems the subject unsuitable to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 3 year OS rate | 3 year | 3 year OS rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORR | 3year | ORR |
| DCR | 3year | DCR |
| 3 year PFS rate | 3 year | 3 year PFS rate |
Contacts
Primary ContactHuang shuang
Outcome results
None listed